Armored CAR T Cells in Multiple Myeloma

November 6, 2018
Eric Smith, MD, PhD

Eric Smith, MD, PhD, discusses the use of armored chimeric antigen receptor T cells in multiple myeloma.

Eric Smith, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of armored chimeric antigen receptor (CAR) T cells in multiple myeloma.

At Memorial Sloan Kettering, armored CAR T cells are used to encode at least 2 genes, 1 being the CAR itself and the second being a gene that gives T cells an advantage. According to Smith, it could be a proinflammatory cytokine that make T cells better killers. It could also be a ligand that is expressed on the surface and interacts with other cells in the tumor microenvironment.